Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
457
-
Total 13F shares, excl. options
-
117M
-
Shares change
-
-2.1M
-
Total reported value, excl. options
-
$22.2B
-
Value change
-
-$422M
-
Put/Call ratio
-
1.28
-
Number of buys
-
206
-
Number of sells
-
-198
-
Price
-
$189.94
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2023
552 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2023.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 457 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 117M shares
of 132M outstanding shares and own 88.72% of the company stock.
Largest 10 shareholders include Capital World Investors (16.5M shares), FMR LLC (12.5M shares), VANGUARD GROUP INC (11.6M shares), BAILLIE GIFFORD & CO (8.39M shares), BlackRock Inc. (8.39M shares), WELLINGTON MANAGEMENT GROUP LLP (6.07M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.89M shares), Dodge & Cox (3.79M shares), T. Rowe Price Investment Management, Inc. (3.24M shares), and JPMORGAN CHASE & CO (3.13M shares).
This table shows the top 457 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.